Knockdown of Histone Methyltransferase hSETD1A Inhibits Progression, Migration, and Invasion in Human Hepatocellular Carcinoma

Xin-sheng Cheng,*† Shi-bo Sun,* Feng Zhong,* Kun He,* and Jie Zhou*

*Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China
†Department of Hepatobiliary Surgery, Shenzhen Nanshan Hospital Affiliated to Guangdong Medical University, Shenzhen, China

Our aim was to study the expression of human SET domain containing protein 1A (hSETD1A) in hepatocellular carcinoma patients and its relationship with human hepatocellular carcinoma cell function. A total of 30 patients with hepatocellular carcinoma were enrolled in this study. The expression of hSETD1A was detected by real-time polymerase chain reaction (PCR) and Western blotting. The immortalized normal human liver cell line including SMMC-7721 was subjected to real-time PCR for hSETD1A mRNA. Furthermore, hSETD1A-small hairpin RNA (shRNA) was used to knock down hSETD1A expression in SMMC-7721 cells. Cell proliferation, cell apoptosis, and cell migration were determined by CCK8, flow cytometry, and Transwell assays. The positive expression rate level of hSETD1A mRNA and protein in liver carcinoma tissues was 73.33%. hSETD1A knockdown using a specific hSETD1A-shRNA inhibited cell proliferation and promoted cell apoptosis in SMMC-7721 cells. It was also found that downregulation of hSETD1A inhibited cell migration ability but did not affect cell invasion. In conclusion, the expression of hSETD1A occurs at a high rate in hepatocellular carcinoma patients. The expression state of hSETD1A may be a prognostic factor in hepatocellular carcinoma.

Key words: Hepatocellular carcinoma (HCC); hSETD1A; Clinical samples; SMMC-7721; Cell function

INTRODUCTION

Hepatocellular carcinoma (HCC), which is frequently caused by hepatitis virus B and C infections, is the fifth most common malignancy and the second leading cause of cancer-related deaths worldwide (1,2). Moreover, its incidence grows continually. The mechanisms of initiation and development of liver neoplasms, which is related to the immunological status of body and gene abnormality, are still unclear (3). In the past few years, patients with HCC have not received unsurpassed clinical efficacy even with improvements in surgical and medical treatments, mainly because of frequent postsurgical recurrence and metastasis (4). The risk of recurrence may be defined by cancer classification based on biomarkers (5,6). A better prognosis with a significant biomarker will help choose an appropriate treatment in advance. However, current methods for HCC diagnosis are classified into the following main categories: imaging [abdominal ultrasonography, magnetic resonance imaging (MRI), contrast-enhanced computed tomography (CT)] and laboratory biomarker analysis [serum alpha-fetoprotein (AFP) levels] (7,8). However, the diagnostic performance of imaging technologies is unsatisfactory, particularly for the diagnosis of small lesions and early stage HCC, which gives us a clue that we may need a useful molecular biomarker (9–11). Unfortunately, some molecular biomarkers related to the risk of cancer recurrence have not been explored completely in HCC patients, and the underlying mechanisms responsible for metastasis remain largely unknown (11–14). Therefore, reliable biomarkers predicting HCC relapse need to be developed, and the mechanisms underlying cancer metastasis need to be explored.

Previous research shows that some proteins, such as programmed death-ligand 1 (PD-L1) (15), heat shock protein 90 (HSP90) (16,17), and SIRT3 (17), are important regulatory molecules in HCC. Their alterations are found in a variety of tumor tissues including breast, gastric, esophageal, lung, bladder, and renal cell cancers (18–23), which means that they may not be the best specific biomarkers for HCC. Furthermore, all previous studies are focused on data in vitro, which suggests that we still know little about these important protein levels in HCC patients.

Address correspondence to Jie Zhou, Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, No. 1838, Guangzhou Avenue North, Guangzhou 510515, China. E-mail: jiezhoudoctor@sohu.com
The hSETD1A gene belongs to the trithorax (TrxG) family of histone methyltransferases (HMT) (24). As we know, alterations in histone modification can drive important cancerous processes such as proliferation, invasion, angiogenesis, and differentiation by perturbing normal genes (25). hSETD1A has been shown to play a role in cell differentiation and tissue development, but very little is known about the role of hSETD1A in cancer, particularly in solid tumors (24,26). Recent studies show that hSETD1A may play an oncogenic role in human colorectal cancer through targeting the Wnt signaling pathway and controlling tumor growth, and in human breast cancer with the link among hSETD1A, MMPs, and metastasis (24).

In the current study, we found that hSETD1A expression was further increased in carcinoma tissue from HCC patients compared with adjacent normal tissue in these patients. It is implied that hSETD1A was associated with the multiple malignant characteristics of HCC. Using real-time polymerase chain reaction (PCR), we explored the mRNA level of hSETD1A in the SMMC-7721 cell line. Furthermore, we synthesized and transfected the special small hairpin RNA (shRNA), which silenced hSETD1A mRNA expression in SMMC-7721. Multiple analyses revealed that the downregulation of hSETD1A was an independent risk factor for cancer cell proliferation, cell apoptosis, and cell migration. The results suggested that the expression of hSETD1A and its relationship with the clinical pathology and prognosis of patients with HCC might provide a basis for the treatment of liver cancer.

**MATERIALS AND METHODS**

**Patient Characteristics, Clinical Features, and Tissue Harvest**

As shown in Table 1, primary HCC tissue was obtained from surgical specimens of 30 hospitalized patients in Nanfang Hospital (Guangzhou, China) between October 2014 and May 2015. A diagnosis of HCC was confirmed by pathology. Liver carcinoma tissue and adjacent normal mucosa from these 30 patients were used to examine the expression of hSETD1A.

**Cell Lines Culture and Treatment**

Human HCC cell line SMMC-7721 [American Type Culture Collection (ATCC), Manassas, VA, USA] was maintained in RPMI-1640 with 5% heat-inactivated fetal bovine serum (FBS) and 1% antibiotic–antimycotic solution (Invitrogen, Carlsbad, CA, USA) at 37°C in a humidified atmosphere of 95% air and 5% CO₂. SMMC-7721 cells were transfected with hSETD1A-shRNA (siRNA sequence: cagaagaatggtacaaatccaag) (50 μM) through LipoFectamine 2000 (Invitrogen) for 24, 48, 72, and 96 h. NC-shRNA (50 μM) was used as a negative control.

| Items                        | Cases (N = 30) |
|------------------------------|---------------|
| Sex                          |               |
| Male                         | 23 (76.67%)   |
| Female                       | 7 (23.33%)    |
| Age                          |               |
| ≤50                          | 14 (46.67%)   |
| ≥50                          | 16 (53.33%)   |
| Different degree             |               |
| High differentiation         | 4 (13.33%)    |
| Medium, low differentiation  | 26 (86.67%)   |
| Tumor size                   |               |
| ≤5 cm                        | 7 (23.33%)    |
| ≥5 cm                        | 23 (76.67%)   |
| Clinical stages              |               |
| Stage I–II                   | 8 (26.67%)    |
| Stage III–IV                 | 22 (73.33%)   |
| HBV infection                |               |
| Negative                     | 3 (10.00%)    |
| Positive                     | 27 (90.00%)   |
| Portal vein thrombosis       |               |
| No                           | 19 (63.33%)   |
| Yes                          | 11 (36.67%)   |
| Level of serum AFP           |               |
| ≤400 μg/L                    | 14 (46.67%)   |
| ≥400 μg/L                    | 16 (53.33%)   |

**Total RNA Isolation, Reverse Transcription, and Real-Time PCR**

Total RNA was isolated by using a UNIQ-10 column and TRIzol Total RNA Isolation Kit (Sangon, Shanghai, China). One microgram of total RNA was used for reverse transcription in a reaction volume of 20 μl using Cloned AMV Reverse Transcriptase (Invitrogen). Two microliters of cDNA was used for real-time PCR using TaKaRa Ex Taq RT-PCR Version 2.1 kit (TaKaRa, Shiga, Japan). Gene-specific PCR primers for hSETD1A and GAPDH are listed in Table 2, and PCR signals were detected with a DNA Engine Opticon 2 Continuous Fluorescence Detection System (Bio-Rad, Hercules, CA, USA). PCR was monitored for 45 cycles using an annealing temperature of 60°C. At the end of the PCR cycles, melt curve analysis and 2% agar electrophoresis were performed to assess the purity of the PCR products. Negative control reactions (no template) were routinely included to monitor potential contamination of reagents. Relative amounts of hSETD1A mRNA were normalized to that of GAPDH mRNA.

**Protein Isolation and Western Blotting Analysis**

The concentration of protein extracts from mouse hepatic microsomes was determined using a BCA kit (Pierce, Rockford, IL, USA), and 20 μg of protein lysates was separated on 10% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) gels followed by transfer to nitrocellulose membranes. Western blotting was performed as previously described (27), and the signal was detected using an ECL system (Millipore, Billerica, MA, USA). Antibodies used in this study included anti-human hSETD1A (1:2,000; Santa Cruz Biotechnology).

**Cell Proliferation Detection**

SMMC-7721 cells were seeded at a density of 1.0 × 10⁵ cells/ml in six-well plates to achieve ~50% confluence the next day and were then transfected with hSETD1A-shRNA (50 μM) using Lipofectamine 2000 (Invitrogen). Thereafter, 100 μl of CCK8 (Dojindo, Japan) solution was added into each well and cells were incubated for 1 h. The absorbance was measured at 450 nm using a microplate reader.

**Apoptosis Assay**

After shRNA transfection for 72 h, the apoptotic cells were quantified using the Annexin-V/Propidium Iodide (PI) apoptosis kit (Multiscience, Hangzhou, China). SMMC-7721 cells were collected, washed with phosphate-buffered saline (PBS), and resuspended in 200 μl of binding buffer containing 5 μl of annexin V (10 μg/ml) for 10 min in the dark. The cells were then incubated with 10 μl of PI (20 μg/ml), and the samples were immediately analyzed using flow cytometry (Epics XL; Beckman Coulter, Brea, CA, USA). Data acquisition and analysis were performed using CellQuest software.

**Transwell Assay**

SMMC-7721 (untransfected), SMMC-7721/NC-shRNA, and SMMC-7721/hSETD1A-shRNA cells were plated at 1.0 × 10⁵ cells/well in 0.5 ml of serum-free medium in 24-well Matrigel-coated Transwell units with polycarbonate filters (8-μm pore size; CoStar Inc., Milpitas, CA, USA). The outer chambers were filled with 0.5 ml of medium supplemented with 10% FBS. After 24 h, the cells were fixed in methanol and stained with crystal violet. The top surface of the membrane was gently scrubbed with a cotton bud, and the cells that had invaded through the membrane filters were counted. The invasion inhibition rate (%) was calculated as \([\frac{(A - B)}{A} \times 100]\), where \(A\) is the invading cells’ percentage for the NC-shRNA group, and \(B\) is the invading cells’ percentage for the hSETD1A-shRNA group.

**Statistical Analysis**

The differences between each group were expressed as the mean ± SD. Statistical significance was assessed by Student’s t-test and one-way analysis of variance (ANOVA) followed by a Tukey post hoc test. Differences were considered statistically significant with a value of \(p < 0.05\).

**RESULTS**

hSETD1A Expressed Differentially in HCC Patients and Human HCC

mRNA level and protein level detection of hSETD1A was conducted using real-time PCR and Western blotting. As shown in Figure 1A and B, both the mRNA level (Fig. 1A) and the protein level (Fig. 1B) of hSETD1A are highly expressed in liver carcinoma tissues compared to the adjacent normal tissues from the same patient.

Validation of hSETD1A Expression in Human HCC by Real-Time PCR

In order to confirm the results obtained from clinical samples, the expression of hSETD1A mRNA was analyzed by real-time PCR in SMMC-7721 compared to HepG2, Hep3B, huh7, and LM3. The results showed that hSETD1A mRNA is relatively highly expressed in SMMC-7721 (Fig. 2). Therefore, we chose SMMC-7721 to complete the following experiment.

Effects of hSETD1A-shRNA on Cell Proliferation

The result in Figure 3A suggests that the hSETD1A mRNA level was effectively silenced by the specific

![Figure 1. Expression of human SET domain containing protein 1A (hSETD1A) in liver carcinoma tissue (C), adjacent normal tissue (N), respectively, of HCC patients as detected by real-time polymerase chain reaction (PCR) (A) and Western blotting (B). **p < 0.01.](image-url)
shRNA. Furthermore, we examined the effects of hSETD1A-shRNA on SMMC-7721 cell proliferation. As shown in Figure 3B, cellular population was reduced time independently at median inhibitory concentration (IC₅₀) levels in the hSETD1A-shRNA group compared to the NC-shRNA group.

**Effects of hSETD1A-shRNA on Cell Apoptosis**

Cell apoptosis was analyzed using flow cytometry after hSETD1A-shRNA transfection for 72 h based on CCK8 results. Compared to the NC-shRNA group, SMMC-7721 cells exposed to hSETD1A-shRNA presented typical promotion from apoptotic morphology with cell shrinkage, nuclear fragmentation, and cellular rupture into debris. The occurrence of apoptosis was significantly higher in cells treated with NC-shRNA as a negative control with respect to the hSETD1A-shRNA group (Fig. 4A and B).

**Effects of hSETD1A-shRNA on Cell Migration**

As shown in Figure 5, the invasive potential of hSETD1A-shRNA cells was not significantly different from that of the NC-shRNA cells (79.14 vs. 77.63%, p > 0.05, data not shown). The migration inhibition rates of the SMMC-7721 cells and the NC-shRNA cells were not significantly different. In addition, the migration potential of the hSETD1A-shRNA cells was significantly lower than that of the NC-shRNA cells (52.26 vs. 80.23%, p < 0.01). The migration inhibition rate in the hSETD1A-shRNA cells reached up to 34.86%. The migration inhibition rates of the SMMC-7721 cells and the NC-shRNA cells were not significantly different.

**DISCUSSION**

Through exploration of the hSETD1A expression in primary HCC, this study found that the expression of the hSETD1A protein in HCC patients was significantly high. Among the enrolled patients in this study, we also found that we had more patients with medium/low differentiation, bigger tumor size (≥ 5 cm), later clinical stage (III–IV), and positive hepatitis B virus (HBV), which implied that patients with these categories may have a high expression of hSETD1A (data now shown). The underlying connection needs further research. Results in vitro showed that expression of the SETD1A protein promoted liver cancer cell proliferation and migration and protected liver cancer cells from apoptosis. These results demonstrated that there may be some connection between hSETD1A and HCC, but there has been no study to make the mechanism known yet. According to previous research, the hSETD1A protein had not been found to be the prognostic factor in liver cancers. This study was the first to report that the expression level of hSETD1A in primary HCC may affect the prognosis and have a negative correlation to cancer cell function.

As we know, the hSETD1A gene belongs to HMT that methylates lysine 4 at histone H3 tails (H3K4), which plays an important role in cancerous processes (24). It is reported that ablation of hSETD1A exhibits some dramatic effects on the trimethylation of H3K4 (H3K4me3) enrichment and expression, which controls gene transcription. However, little is known about the target genes affected by the altered H3K4me3 expression.

![Figure 2. Expression of hSETD1A in SMCC-7721, LM3, Hep3B, huh7, and HepG2 as detected by real-time PCR. *p < 0.05; **p < 0.01.](image1)

![Figure 3. Downregulation of hSETD1A promotes growth of SMMC-7721 cells in vitro. (A) Expression of hSETD1A in SMMC-7721 after downregulation of hSETD1A. (B) Cell numbers were counted in the following time points: 24, 48, 72, and 96 h. *p < 0.05; **p < 0.01; ***p < 0.001.](image2)
Figure 4. Induction of apoptosis change. (A) SMMC-7721 cells were transfected with small hairpin RNAs (shRNAs) for 72 h before being harvested for apoptosis test. (B) Percentage of SMMC-7721 cell apoptosis in the 72-h time point. ***p < 0.001.

Figure 5. Suppressive effect of shRNA-mediated hSETD1A silencing on the migration potential of SMMC-7721 cells. (A) Migration tests. (B) Percentage of SMMC-7721 cell migration in the 24-h time point. **p < 0.01.
during carcinogenesis and whether hSETD1A is correlated to the increase of H3K4me3 levels. Previous research revealed that hSET works with mixed lineage leukemia (MLL) as a complex that is required for enzymatic activity (28,29). To understand the target gene specificity of hSET1/MLL complexes and how it works in specific types of cancers such as liver cancer will not only provide new insight into the pathogenesis of liver cancer but also lead to new strategies for cancer diagnosis and therapeutic approaches.

Recently, it was shown that histone can interact with β-catenin (30), a master regulator of the canonical Wnt signaling pathway, in human embryonic kidney 293 (HEK293) cells (31) and colorectal cancer cells (32,33). On the basis of these studies, they depicted a hypothesis which is that β-catenin and hSETD1A are upregulated and interact in the nucleus; β-catenin then recruits hSETD1A to putative Wnt promoters to confer H3K4me3, assemble preinitiation complex, activate Wnt target genes, and subsequently promote cellular growth. Identifying and targeting the β-catenin partners or cofactors, such as hSETD1A, could be an effective therapeutic approach for inhibiting the Wnt signaling pathway in colorectal cancer (24). Future studies validating this hypothesis and investigating whether hSETD1A works similarly in various types of cancers, such as HCC, may significantly contribute to our understanding of the role of hSETD1A in cancer diseases.

ACKNOWLEDGMENT: The authors declare no conflicts of interest.

REFERENCES

1. Bosetti, C.; Turati, F.; La Vecchia, C. Hepatocellular carcinoma epidemiology. Best. Pract. Res. Clin. Gastroenterol. 28:753–770; 2014.
2. Xu, J.; Li, J.; Chen, J.; Liu, Z. J. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy-meta-analysis. Adv. Clin. Exp. Med. 24:331–340; 2015.
3. Chang, Q.; Zhang, Y.; Beezhold, K. J.; Bhatia, D.; Zhao, H.; Chen, J.; Castranova, V.; Shi, X.; Chen, F. Sustained JNK1 activation is associated with altered histone H3 methyla-
4. tion in human liver cancer. J. Hepatol. 50:323–333; 2009.
5. Ting, C. T.; Li, W. C.; Chen, C. Y.; Tsai, T. H. Preventive and therapeutic role of traditional Chinese herbal medicine in hepatocellular carcinoma. J. Chin. Med. Assoc. 78:139–144; 2015.
6. Alsinet, C.; Villanueva, A. Genomic prognostic markers in hepatocellular carcinoma. Gastroenterol. Hepatol. 35:94–101; 2012.
7. Hosaka, T.; Ikeda, K.; Kobayashi, M.; Hirakawa, M.; Kawamura, Y.; Yatsui, H.; Sezaki, H.; Akuta, N.; Suzuki, F.; Suzuki, Y.; Saitoh, S.; Arase, Y.; Kumada, H. Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma. Liver Int. 29:736–742; 2009.
8. Enomoto, H.; Ishii, A.; Imanishi, H.; Saito, M.; Tanaka, H.; Iwata, Y.; Sakai, Y.; Iwai, T.; Yoh, K.; Takashima, T.; Yoshikawa, S.; Aizawa, N.; Yamamoto, T.; Ikeda, N.; Shimomura, S.; Iijima, H.; Hirota, S.; Nishiguchi, S. [A case of hepatocellular carcinoma with autoimmune hepatitis showing marked reduction of tumors by oral administr-
9. ation of UFT-E]. Gan To Kagaku Ryoho 37:919–922; 2010.
10. Lamerz, R.; Runge, M.; Stieber, P.; Meissner, E. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Anticancer Res. 19:2489–2493; 1999.
11. Lencioni, R. Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. Oncology 78(Suppl. 1):107–112; 2010.
12. Lencioni, R.; Crocetti, L.; De Simone, P.; Filippioni, F. Loco-regional interventional treatment of hepatocellular carcinoma: Techniques, outcomes, and future prospects. Transpl. Int. 23:698–703; 2010.
13. Stefanick, P.; Cianciara, J.; Wiercinska-Drapalo, A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 16:418–424; 2010.
14. Xiao, J. F.; Varghese, R. S.; Zhou, B.; Nezami Ranjbar, M. R.; Zhao, Y.; Tsai, T. H.; Di Poto, C.; Wang, J.; Goertitz, D.; Luo, Y.; Cheema, A. K.; Sarhan, N.; Soliman, H.; Tadesse, M. G.; Ziada, D. H.; Ressom, H. W. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. J. Proteome Res. 11:5914–5923; 2012.
15. Morris-Stiff, G.; Gomez, D.; Prasad, K. R. C-reactive protein in liver cancer surgery. Eur. J. Surg. Oncol. 34:727–729; 2008.
16. Hong, Y.; Huang, J. Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma. World J. Hepatol. 7:1581–1585; 2015.
17. Kan, G.; Dong, W. The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology. Eur. Rev. Med. Pharmacol. Sci. 19:3063–3071; 2015.
18. Yoo, S. H.; Kim, H. Y.; Rho, J. H.; Jeong, S. Y.; Yun, J.; Yun, I.; Park, H. T.; Yoo, Y. H. Targeted inhibition of mitochondrial Hsp90 induces mitochondrial elongation in Hep3B hepatocellular carcinoma cells undergoing apoptosis by increasing the ROS level. Int. J. Oncol. 47(5):1783–1792; 2015.
19. Gao, M.; Geng, X. P.; Xiang, H. P. HSP90 and SIRT3 expression in hepatocellular carcinoma and their effect on invasive capability of human hepatocellular carcinoma cells. Asian Pac. J. Trop. Med. 8:305–308; 2015.
20. Eccles, S. A. Metastasis and the tumor microenvironment: A Joint Metastasis Research Society-AACR Conference—Research on metastasis: Part 2. I Drugs 13:768–771; 2010.
21. Havik, B.; Bramham, C. R. Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines. Oncol. Rep. 17:1501–1510; 2007.
22. Homet Moreno, B.; Parisi, G.; Robert, L.; Ribas, A. Anti-PD-1 therapy in melanoma. Semin. Oncol. 42:466–473; 2015.
23. Giraldo, N. A.; Bech, E.; Pagès, F.; Skliris, G.; Verkarre, V.; Vanó, Y.; Mejean, A.; Saint-Aubert, N.; Lacroix, L.; Natario, I.; Lupo, A.; Alifano, M.; Damotte, D.; Cazes, A.; Triebel, F.; Freeman, G. J.; Dieu-Nosjean, M. C.; Oudard, S.; Fridman, W. H.; Santés-Firdman, C. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res 21:3031–3040; 2015.
24. Wu, P.; Wu, D.; Li, L.; Chai, Y.; Huang, J. PD-L1 and survival in solid tumors: A meta-analysis. PLoS One 10:e0131403; 2015.
23. Derks, S.; Nason, K. S.; Liao, X.; Stachler, M. D.; Liu, K. X.; Liu, J. B.; Sicinska, E.; Goldberg, M. S.; Freeman, G. J.; Rodig, S. J.; Davison, J. M.; Bass, A. J. Epithelial PD-L2 expression marks Barrett’s esophagus and esophageal adenocarcinoma. Cancer Immunol. Res. 3:1123–1129; 2015.

24. Salz, T.; Li, G.; Kaye, F.; Zhou, L.; Qiu, Y.; Huang, S. hSETD1A regulates Wnt target genes and controls tumor growth of colorectal cancer cells. Cancer Res. 74:775–786; 2014.

25. Landan, G.; Cohen, N. M.; Mukamel, Z.; Bar, A.; Molchadsky, A.; Brosh, R.; Horn-Sahan, S.; Zalcenstein, D. A.; Goldfinger, N.; Zundelevich, A.; Gal-Yam, E. N.; Rotter, V.; Tanay, A. Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nat. Genet. 44:1207–1214; 2012.

26. Salz, T.; Deng, C.; Pampo, C.; Siemann, D.; Qiu, Y.; Brown, K.; Huang, S. Histone methyltransferase hSETD1A is a novel regulator of metastasis in breast cancer. Mol. Cancer Res. 13:461–469; 2015.

27. Ruan, W.-D.; Wang, P.; Feng, S.; Xue, Y.; Zhang, B. MicroRNA-497 inhibits cell proliferation, migration, and invasion by targeting AMOT in human osteosarcoma cells. Onco Targets Ther. 9:303–313; 2016.

28. Mohan, M.; Lin, C.; Guest, E.; Shilatifard, A. Licensed to elongate: A molecular mechanism for MLL-based leukemogenesis. Nat. Rev. Cancer 10:721–728; 2010.

29. Shilatifard, A. The COMPASS family of histone H3K4 methylases: Mechanisms of regulation in development and disease pathogenesis. Annu. Rev. Biochem. 81:65–95; 2012.

30. Hoffmeyer, K.; Raggioli, A.; Rudloff, S.; Anton, R.; Hierholzer, A.; Del Valle, I.; Hein, K.; Vogt, R.; Kemler, R. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science 336:1549–1554; 2012.

31. Huang, X.; Xu, J.; Huang, M.; Li, J.; Dai, L.; Dai, K.; Zhang, X. Histone deacetylase1 promotes TGF-beta1-mediated early chondrogenesis through down-regulating canonical Wnt signaling. Biochem. Biophys. Res. Commun. 453:810–816; 2014.

32. Li, Q.; Chen, H. Silencing of Wnt5a during colon cancer metastasis involves histone modifications. Epigenetics 7:551–558; 2012.

33. Kim, H. A.; Koo, B. K.; Cho, J. H.; Kim, Y. Y.; Seong, J.; Chang, H. J.; Oh, Y. M.; Stange, D. E.; Park, J. G.; Hwang, D.; Kong, Y. Y. Notch1 counteracts WNT/beta-catenin signaling through chromatin modification in colorectal cancer. J. Clin. Invest. 122:3248–3259; 2012.